Medication info
Narigenta Duo Extended Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Narigenta Duo Extended Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›2.5mg / 1 tablet
Manufacturer / importer
Pharmgen Science Co., Ltd.
Appearance
Oval extended release tablet, white to almost white in color, engraved with N251 on one side
Packaging
28 tablets/box (7 tablets/PTP x 4), 30 tablets/bottle
Approval status
Active

MFDS item code 202400606 · Approved 2024.03.22 · Insurance code 670105540

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate, if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug should be discontinued immediately.

Ingredients

Manufacturer
Pharmgen Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with dietary and exercise regimens to help control blood sugar in patients with type 2 diabetes who use both linagliptin and metformin. It aids in managing blood sugar more effectively. Therefore, it is used to improve blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted as appropriate, if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be equivalent to the patient's current doses of linagliptin and extended-release metformin hydrochloride. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug should be discontinued immediately.

Precautions

This medication's active ingredient, metformin hydrochloride, can rarely cause serious lactic acidosis or hypoglycemia, so caution is needed. This medication should not be administered to certain patients. For example, it should not be used in individuals allergic to this medication or its ingredients, in cases of type 1 diabetes, severe renal impairment, severe liver dysfunction, acute alcohol intoxication, heart failure, or during pregnancy. Due to the risk of hypoglycemia, blood sugar levels should be monitored carefully, especially when taken in combination with sulfonylureas or insulin. Lactic acidosis is a very rare side effect but poses significant risks; hence, the medication should be discontinued immediately and a doctor consulted in cases of dehydration, severe infection, or a rapid decline in heart or kidney function. Kidney function has a significant impact, so regular kidney function tests should be conducted before and during treatment. Patients with weak heart function or cardiovascular diseases such as acute myocardial infarction should use this medication cautiously. If iodine contrast is administered during radiological examinations, the medication should be stopped and kidney function reassessed before resuming. The medication should be discontinued for a certain period before and after surgery; it can be resumed once kidney function returns to normal post-surgery. If acute pancreatitis or blistering skin conditions are suspected while taking this medication, the patient should inform a doctor immediately and stop taking the medication. Metformin can lower Vitamin B12 levels; therefore, it is advisable to regularly check for Vitamin B12 deficiency during long-term use. This medication should be swallowed whole and not crushed or chewed, and the tablet shell may appear in stool, which is normal. Due to potential interactions with other medications, especially those that can affect kidney function, caution is advised when used in combination with other drugs. It is recommended to avoid using this medication during pregnancy or breastfeeding, and consult a doctor if planning a pregnancy. Safety and efficacy in pediatric patients have not been established, so it is preferable not to use it in this population. Elderly individuals are at higher risk for decreased kidney function, so treatment should start at the minimum dosage and kidney function should be monitored regularly. In cases of overdose, there is a risk of lactic acidosis, requiring immediate medical treatment, which may include blood dialysis. This medication should be kept out of reach of children and stored away from moisture.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disorders
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 136 more
  • abdominal pain
  • oral ulcers
  • liver function abnormalities
  • hepatitis
  • angioedema
  • urticaria
  • pruritus
  • erythema
  • rash
  • dermatitis herpetiformis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity reactions
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • fracture
  • hand fracture
  • chest discomfort
  • asthenia
  • pain
  • epistaxis
  • oropharyngeal pain
  • voice disorders
  • allergic rhinitis
  • exertional dyspnea
  • wet cough
  • runny nose
  • lung mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • increased serum triglycerides
  • increased urine albumin/creatinine ratio
  • positive urine leukocytes
  • decreased hemoglobin
  • increased serum potassium
  • increased serum creatinine
  • increased serum creatine phosphokinase
  • increased ALT
  • male pattern baldness
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • confusional state
  • nocturia
  • dermatitis
  • hypertension
  • erectile dysfunction
  • thyroid enlargement
  • vitreous hemorrhage
  • stomatitis
  • mediastinitis
  • rhinitis
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • rectal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • dizziness
  • sensory impairment
  • headache
  • subdural effusion
  • pruritus
  • dry eye
  • cataract
  • ocular discomfort

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is also safe to store it at room temperature between 1 degree and 30 degrees Celsius, avoiding extremely hot or cold places.

Appearance and packaging

Appearance

Oval extended release tablet, white to almost white in color, engraved with N251 on one side

Package unit

28 tablets/box (7 tablets/PTP x 4), 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.